Lenacapavir

GS-9770, atazanavir (ATV), darunavir (DRV), amprenavir (APV), bictegravir (BIC), elvitegravir (EVG), lenacapavir (LEN), tenofovir alafenamide (TAF), emtricitabine (FTC), efavirenz (EFV), stavudine (d4T), the RSV control inhibitor YM-53403, and the SARS CoV-2 control inhibitor remdesivir (RDV) were all synthesized at Gilead Sciences (Foster City, CA). Ribavirin (RBV) was purchased from Combi-Blocks (San Diego, CA). The protein synthesis inhibitor puromycin and the HIV-positive control azidothymidine (AZT) were purchased from Sigma-Aldrich (St. Louis, MO). The HBV control inhibitor ND-654 was purchased from Pharmaron (Beijing, China). The HCV protease inhibitor danoprevir was purchased from Selleck Chemicals (Houston, TX). All drug stocks were prepared in 100% dimethyl sulfoxide (DMSO) and stored frozen at −20°C.

Lenacapavir and a generic internal small-molecule standard used for the LEN bioanalysis experiments were both synthesized at Gilead Sciences (Foster City, CA) and subjected to a standard quality control analysis. For animal dosing studies, LEN was formulated as a sterile, preservative-free, injectable solution (309 mg/ml in 57.5% w/v polyethylene glycol 300 in water) and stored at ambient temperature, protected from light, until dosing.